 Connection
Amrut Ambardekar to Amyloid Neuropathies, Familial
This is a "connection" page, showing publications Amrut Ambardekar has written about Amyloid Neuropathies, Familial.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.394 |
|
|
|
-
Sarswat N, Ambardekar AV, Alexander KM, Cuddy SA, Stern L, Poulsen SH, Tschöpe C, Sekijima Y, Sheikh FH, Griffin JM, Judge DP, Gillmore J, Masri A. Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM. Future Cardiol. 2026 Feb; 22(2):119-133.
Score: 0.241
-
Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J, Ruberg FL. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. J Am Coll Cardiol. 2026 Feb 10; 87(5):549-565.
Score: 0.236
-
Masri A, Judge DP, Ruberg FL, Gillmore JD, Grodin JL, Obici L, Maurer MS, Fontana M, Poulsen SH, van der Meer P, Cheng RK, Cuddy SAM, Ambardekar AV, Xiong K, Cao X, Murtagh G, Siddhanti S, Castaño A, Tamby JF, Fox JC, Alexander KM, Witteles R. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. J Am Coll Cardiol. 2026 Feb 10; 87(5):490-501.
Score: 0.235
-
Dasgupta N, Poulsen SH, Emdin M, Ambardekar AV, Shah KB, Hennum L, Marwah R, Allison M, Shivanna P, Siddhanti S, Tamby JF, Falvey H, Grodin JL. Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy. Am J Cardiovasc Drugs. 2025 Nov; 25(6):829-839.
Score: 0.232
-
Maurer MS, Judge DP, Gillmore JD, Garcia-Pavia P, Masri A, Cappelli F, Alexander KM, Sarswat N, Grogan M, Ambardekar AV, Ducharme A, Poulsen SH, Lam K, Obici L, Soman P, Rao S, Tamby JF, Castaño A, Fox JC, Adam B, Chepyala SR, Poland B, Sinha U, Fontana M. Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1911-1923.
Score: 0.229
-
Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, García-Pavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 04; 151(9):601-611.
Score: 0.221
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|